Mochida Pharmaceutical Co., Ltd. Share Price

Equities

4534

JP3922800002

Pharmaceuticals

Market Closed - Japan Exchange 11:30:00 01/05/2024 am IST 5-day change 1st Jan Change
3,205 JPY +0.47% Intraday chart for Mochida Pharmaceutical Co., Ltd. +1.26% -1.99%

Financials

Sales 2024 * 102B 657M 54B Sales 2025 * 106B 683M 56.11B Capitalization 114B 733M 60.2B
Net income 2024 * 4.4B 28.36M 2.33B Net income 2025 * 5.9B 38.03M 3.12B EV / Sales 2024 * 0.5 x
Net cash position 2024 * 62.97B 406M 33.33B Net cash position 2025 * 64.14B 413M 33.96B EV / Sales 2025 * 0.47 x
P/E ratio 2024 *
25.9 x
P/E ratio 2025 *
19.3 x
Employees 1,529
Yield 2024 *
2.5%
Yield 2025 *
2.5%
Free-Float 53.94%
More Fundamentals * Assessed data
Dynamic Chart
Hidehiro Imatsu named president of Goldman Sachs Japan RE
Tranche Update on Mochida Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on May 15, 2023. CI
Mochida Pharmaceutical Co., Ltd.'s Equity Buyback announced on May 15, 2023, has closed with 1,080,000 shares, representing 2.97% for ¥3,485.1 million. CI
Mochida Pharmaceutical Co., Ltd. Provides Dividend Guidance for the Year Ending March 31, 2024 CI
Mochida Pharmaceutical Co., Ltd. Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2024 CI
Tranche Update on Mochida Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on May 15, 2023. CI
Mochida Pharmaceutical Co., Ltd. Announces Dividend for the Second Quarter Ended September 30, 2023, Payable on December 1, 2023 and Provides Dividend Guidance for the Year Ending March 31, 2024 CI
Mochida Pharmaceutical Co., Ltd. Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2024 CI
Tranche Update on Mochida Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on May 15, 2023. CI
Mochida Pharmaceutical Co., Ltd. Provides Second Quarter-End and Year-End Dividend Guidance for the Fiscal Year Ending March 31, 2024 CI
Mochida Pharmaceutical Co., Ltd. Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2024 CI
Tranche Update on Mochida Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on May 15, 2023. CI
Mochida Pharmaceutical's Fiscal Full-Year Profit Falls 37.1% MT
Mochida Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended March 31, 2023 CI
Mochida Pharmaceutical Co., Ltd. Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2024 CI
More news
1 day+0.47%
1 week+1.26%
Current month-0.47%
1 month+0.16%
3 months-3.32%
Current year-1.99%
More quotes
1 week
3 090.00
Extreme 3090
3 210.00
1 month
3 060.00
Extreme 3060
3 230.00
Current year
3 055.00
Extreme 3055
3 430.00
1 year
3 055.00
Extreme 3055
3 745.00
3 years
3 025.00
Extreme 3025
4 000.00
5 years
3 025.00
Extreme 3025
5 380.00
10 years
2 985.00
Extreme 2985
6 110.00
More quotes
Managers TitleAgeSince
President 65 01/91/01
Chief Administrative Officer 61 01/17/01
Chief Tech/Sci/R&D Officer 66 01/82/01
Members of the board TitleAgeSince
President 65 01/91/01
Director/Board Member 59 29/21/29
Director/Board Member 66 01/80/01
More insiders
Date Price Change Volume
01/24/01 3,205 +0.47% 18,600
30/24/30 3,190 +1.43% 40,900
26/24/26 3,145 +0.96% 90,700
25/24/25 3,115 -1.27% 25,000
24/24/24 3,155 -0.32% 20,200

Delayed Quote Japan Exchange, May 01, 2024 at 11:30 am IST

More quotes
Mochida Pharmaceutical Co Ltd is a Japan-based company principally engaged in the production and sale of drugs. The Pharmaceutical-related segment is engaged in the manufacture, purchase and sale of pharmaceutical products. The Company also conducts brokerage and management of real estate properties, the maintenance and management of buildings, the agency of personal affairs, accounting and purchasing businesses. The Healthcare segment is involved in the manufacture, purchase and sale of quasi drugs and cosmetic products.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
3,205 JPY
Average target price
3,200 JPY
Spread / Average Target
-0.16%
Consensus